You are here: Industry Insights > Bispecific Antibody

News List

Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046 prnasia
October 18, 2021
Alphamab Oncology (stock code: 9966.HK), announced that the first phase III pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-01) has successfully completed enrollment of all patients.
Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021 prnasia
October 13, 2021
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer...
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit prnasia
September 28, 2021
Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.
FDA Issues Final Guidance on Bispecific Antibody Development Programs americanpharmaceuticalreview
May 26, 2021
The U.S. FDA issued a final guidance on Bispecific Antibody Development Programs. This final guidance provides recommendations for industry and other parties involved in developing bispecific antibodies, which are antibody-based products that target ...
Roche reveals new bispecific antibody data in blood cancers pharmatimes
December 10, 2020
Swiss pharma company Roche has revealed positive early data for its investigational bispecific antibodies mosunetuzumab, glofitamab and cevostamab in a range of blood cancer types.
Bispecific antibodies will mature after 2021, $6bn estimated sales in oncology by 2025: GlobalData expresspharma
October 09, 2020
There are 106 bispecific antibody molecules in the pipeline and 263 ongoing/planning to enrol clinical trials involving a bispecific antibody.
Abbvie, Genmab Enter $750M Antibody Alliance contractpharma
June 11, 2020
To jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates.
EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations en-cphi
April 23, 2020
EpimAb receives exclusive access to newly discovered target combinations in order to expand its proprietary pipeline
Regeneron records 80% complete response rate in lymphoma trial fiercebiotech
January 03, 2019
Regeneron’s CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a small trial of patients with relapsed or refractory follicular lymphoma....
MacroGenics halts trials of cancer drug after FDA partial hold fiercebiotech
December 28, 2018
Potential liver-related side effects have led to the FDA placing a partial clinical hold on a MacroGenics-developed bispecific antibody for cancer.....

Previous page 1 2 3 Next page